sábado, 1 de octubre de 2016

Confirmation of translatability and functionality certifies the dual endothelin1/VEGFsp receptor (DEspR) protein | BMC Molecular Biology | Full Text

Confirmation of translatability and functionality certifies the dual endothelin1/VEGFsp receptor (DEspR) protein | BMC Molecular Biology | Full Text

Biomed Central

BMC Molecular Biology

 
OPEN ACCESS

Confirmation of translatability and functionality certifies the dual endothelin1/VEGFsp receptor (DEspR) protein

  • Victoria L. M. Herrera,
  • Martin Steffen,
  • Ann Marie Moran,
  • Glaiza A. Tan,
  • Khristine A. Pasion,
  • Keith Rivera,
  • Darryl J. Pappin and
  • Nelson Ruiz-OpazoEmail author
BMC Molecular BiologyBMC series – open, inclusive and trusted201617:15
DOI: 10.1186/s12867-016-0066-8
Received: 28 January 2016
Accepted: 20 May 2016
Published: 14 June 2016

Abstract

Background

In contrast to rat and mouse databases, the NCBI gene database lists the human dual-endothelin1/VEGFsp receptor (DEspR, formerly Dear) as a unitary transcribed pseudogene due to a stop [TGA]-codon at codon#14 in automated DNA and RNA sequences. However, re-analysis is needed given prior single gene studies detected a tryptophan [TGG]-codon#14 by manual Sanger sequencing, demonstrated DEspR translatability and functionality, and since the demonstration of actual non-translatability through expression studies, the standard-of-excellence for pseudogene designation, has not been performed. Re-analysis must meet UNIPROT criteria for demonstration of a protein’s existence at the highest (protein) level, which a priori, would override DNA- or RNA-based deductions.

Methods

To dissect the nucleotide sequence discrepancy, we performed Maxam–Gilbert sequencing and reviewed 727 RNA-seq entries. To comply with the highest level multiple UNIPROT criteria for determining DEspR’s existence, we performed various experiments using multiple anti-DEspR monoclonal antibodies (mAbs) targeting distinct DEspR epitopes with one spanning the contested tryptophan [TGG]-codon#14, assessing: (a) DEspR protein expression, (b) predicted full-length protein size, (c) sequence-predicted protein-specific properties beyond codon#14: receptor glycosylation and internalization, (d) protein-partner interactions, and (e) DEspR functionality via DEspR-inhibition effects.

Results

Maxam–Gilbert sequencing and some RNA-seq entries demonstrate two guanines, hence a tryptophan [TGG]-codon#14 within a compression site spanning an error-prone compression sequence motif. Western blot analysis using anti-DEspR mAbs targeting distinct DEspR epitopes detect the identical glycosylated 17.5 kDa pull-down protein. Decrease in DEspR-protein size after PNGase-F digest demonstrates post-translational glycosylation, concordant with the consensus-glycosylation site beyond codon#14. Like other small single-transmembrane proteins, mass spectrometry analysis of anti-DEspR mAb pull-down proteins do not detect DEspR, but detect DEspR-protein interactions with proteins implicated in intracellular trafficking and cancer. FACS analyses also detect DEspR-protein in different human cancer stem-like cells (CSCs). DEspR-inhibition studies identify DEspR-roles in CSC survival and growth. Live cell imaging detects fluorescently-labeled anti-DEspR mAb targeted-receptor internalization, concordant with the single internalization-recognition sequence also located beyond codon#14.

Conclusions

Data confirm translatability of DEspR, the full-length DEspR protein beyond codon#14, and elucidate DEspR-specific functionality. Along with detection of the tryptophan [TGG]-codon#14 within an error-prone compression site, cumulative data demonstrating DEspR protein existence fulfill multiple UNIPROT criteria, thus refuting its pseudogene designation.

Keywords

DEspR Pseudogene DEspR protein–protein interactions

No hay comentarios:

Publicar un comentario